{
  "id": "415f7c6a5803ad06",
  "title": "Enhertu Plus Pertuzumab Approved for First - Line HER2+ Breast Cancer",
  "description": "20251229T164500Z",
  "content": "",
  "source": "cancertherapyadvisor.com",
  "source_url": "https://www.cancertherapyadvisor.com/news/enhertu-plus-pertuzumab-approved-for-first-line-her2-breast-cancer/",
  "published_at": "20251229T164500Z",
  "fetched_at": "2025-12-30T00:22:59.073919+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "https://www.cancertherapyadvisor.com/news/enhertu-plus-pertuzumab-approved-for-first-line-her2-breast-cancer/",
    "url_mobile": "",
    "title": "Enhertu Plus Pertuzumab Approved for First - Line HER2+ Breast Cancer",
    "seendate": "20251229T164500Z",
    "socialimage": "https://www.cancertherapyadvisor.com/wp-content/uploads/sites/12/2024/01/CTA_1200x675.png",
    "domain": "cancertherapyadvisor.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}